胃癌术后全身化疗联合腹腔化疗对患者免疫功能及预后的影响

Influence of chemotherapy combined with intraperitoneal chemotherapy on immune function and prognosis of gastric cancer patients

目的探讨胃癌根治术后腹腔灌注化疗联合全身静脉化疗对免疫功能和预后的影响。方法选取2008年2月至2012年2月间收治的胃癌患者120例,按照随机数字表法分为观察组和对照组,每组60例。观察组患者术后行全身静脉化疗联合腹腔化疗,对照组患者仅给予全身静脉化疗,比较两组患者T细胞亚群、卡氏体力状态(KPS)评分、肿瘤复发率及生存率情况。结果观察组患者治疗后CD4^+、CD4^+/CD8^+水平与对照组比较,差异无统计学意义(P>0.05);观察组患者2、3年生存率明显高于对照组(P<0.05),术后肿瘤复发率明显低于对照组(P<0.05);观察组患者KPS评分有效率高于对照组,差异有统计学意义(P<0.05)。结论胃癌根治术后辅助全身静脉化疗并联合腹腔区域性化疗,可降低胃癌复发率、提高患者生存率、改善患者的体力状况和生存质量,值得临床推广。

Objective To investigate the influence of chemotherapy combined with intraperitoneal chemotherapy on immune function and prognosis of gastric cancer patients. Methods 120 cases of radical gastrectomy for gastric cancer were enrolled in the study and randomly divided into the observation group and the control group, with 60 cases in each group. The observation group was treated with systemic intravenous chemotherapy combined with intraperitoneal chemotherapy, and the control group was only given systemic intravenous chemotherapy. The level of T cell subsets, Karnofsky performance status （KPS） score, tumor recurrence rate and survival rate of the two groups were compared. Results The levels of CD4 ＋ and CD4 ＋ / CD8 ＋in the observation group showed no significant difference compared with the control group （P 〉 0. 05 ） ; The 2-yr and 3-yr survival rate were significantly higher than those of the control group （P 〈 0. 05）, and the recurrence rate of tumor was significantly lower than that of the control group （ P 〈 0. 05 ）. KPS score was sig- nificantly higher than that of the control group （ P 〈 0. 05 ）. Conclusion Systemic venous chemotherapy combined with intraperitoneal chemotherapy can reduce the recurrence rate, improve the survival rate and physical condition and quality of life for patients with radical gastreetomy for gastric cancer.